$OGEN
ORAGENICS INC Stock $ogen

$ogen Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000119312517327138 Filed on October 31, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cost Of Revenue	$0.00		$0.00
YoY Change
Gross Profit	$0.00		$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin	$600.0K	$930.0K	$1.100M
YoY Change	-35.48%	-15.45%	28.82%
% of Gross Profit
Research & Development	$820.0K	$996.5K	$924.8K
YoY Change	-53.93%	7.75%	-16.23%
% of Gross Profit
Depreciation & Amortization	$20.00K	$10.00K	$20.00K
YoY Change	0.0%	-50.0%	0.0%
% of Gross Profit
Operating Expenses	$1.412M	$1.922M	$2.027M
YoY Change	-47.84%	-5.19%	8.61%
Operating Profit	-$1.412M	-$1.922M	-$2.027M
YoY Change	-47.84%	-5.19%	8.61%
Interest Expense	-$50.00K	$105.9K	$1.291K
YoY Change	-350.0%	8102.48%	-96.74%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$145.7K	$21.10K
YoY Change	-100.0%	-790.67%	-161.76%
Pretax Income	-$1.460M	-$2.067M	-$2.006M
YoY Change	-45.52%	3.07%	5.55%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.461M	-$2.067M	-$1.963M
YoY Change	-45.39%	5.31%	5.33%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$296.1K	-$419.9K	-$399.2K
COMMON SHARES
Basic Shares Outstanding	49.27M shares	49.27M shares	49.11M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.170M	$2.920M	$5.120M
YoY Change	51.23%	-42.97%	-24.04%
Cash & Equivalents	$6.166M	$2.923M	$5.117M
Short-Term Investments
Other Short-Term Assets	$1.030M	$2.180M	$170.0K
YoY Change	635.71%	1182.35%	0.0%
Inventory			$0.00
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$7.193M	$5.101M	$5.288M
YoY Change	70.39%	-3.54%	-26.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$21.66K	$34.12K	$107.1K
YoY Change	-75.24%	-68.14%	-32.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$21.66K	$34.12K	$107.1K
YoY Change	-75.24%	-68.14%	-32.75%
TOTAL ASSETS
Total Short-Term Assets	$7.193M	$5.101M	$5.288M
Total Long-Term Assets	$21.66K	$34.12K	$107.1K
Total Assets	$7.215M	$5.135M	$5.396M
YoY Change	67.43%	-4.82%	-26.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$820.0K	$1.590M	$790.0K
YoY Change	-35.94%	101.27%	3.95%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$80.00K	$130.0K	$110.0K
YoY Change	14.29%	18.18%	-97.85%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$898.5K	$1.722M	$909.3K
YoY Change	-33.12%	89.42%	-84.55%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$2.400M	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$2.400M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$898.5K	$1.722M	$909.3K
Total Long-Term Liabilities	$0.00	$2.400M	$0.00
Total Liabilities	$900.0K	$4.122M	$910.0K
YoY Change	-32.84%	353.0%	-84.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$101.4M	-$99.94M	-$91.99M
YoY Change	7.11%	8.64%	7.68%
Common Stock	$4.928K	$49.27K	$97.50M
YoY Change	-99.99%	-99.95%	12.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.316M	$1.013M	$4.486M
YoY Change
Total Liabilities & Shareholders Equity	$7.215M	$5.135M	$5.396M
YoY Change	67.43%	-4.82%	-26.99%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q3
OPERATING ACTIVITIES
Net Income	-$1.461M	-$2.067M	-$1.963M
YoY Change	-45.39%	5.31%	5.33%
Depreciation, Depletion And Amortization	$20.00K	$10.00K	$20.00K
YoY Change	0.0%	-50.0%	0.0%
Cash From Operating Activities	-$1.350M	-$1.340M	-$1.710M
YoY Change	-31.82%	-21.64%	34.65%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$30.00K
YoY Change		-100.0%	200.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$450.0K
YoY Change		-100.0%
Cash From Investing Activities	$0.00	$0.00	$430.0K
YoY Change		-100.0%	-4400.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.600M	2.180M	950.0K
YoY Change	389.36%	129.47%	-3266.67%
NET CHANGE
Cash From Operating Activities	-1.350M	-1.340M	-1.710M
Cash From Investing Activities	0.000	0.000	430.0K
Cash From Financing Activities	4.600M	2.180M	950.0K
Net Change In Cash	3.250M	840.0K	-330.0K
YoY Change	-412.5%	-354.55%	-74.81%
FREE CASH FLOW
Cash From Operating Activities	-$1.350M	-$1.340M	-$1.710M
Capital Expenditures	$0.00	$0.00	-$30.00K
Free Cash Flow	-$1.350M	-$1.340M	-$1.680M
YoY Change	-31.82%	-20.24%	33.33%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q3	us-gaap	Assets Current AssetsCurrent	5101198
CY2017Q2	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	128070
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	49274219	shares
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5116631
CY2017Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	99658285
CY2017Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1594245
CY2017Q3	us-gaap	Assets Assets	5135318
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2923454
CY2017Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	4081569
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49274219	shares
CY2017Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	11129031	shares
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49274219	shares
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	49274
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5135318
CY2017Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2400000
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1722315
CY2017Q3	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	2400000
CY2017Q3	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2017Q3	us-gaap	Preferred Stock Value PreferredStockValue	1245508
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	769629
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34120
CY2017Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	1408115
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-99940064
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	1013003
CY2017Q3	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	128070
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5083355
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	175584	shares
CY2016Q4	us-gaap	Assets Current AssetsCurrent	4221704
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	97616444
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1277066
CY2016Q4	us-gaap	Assets Assets	4309166
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4080618
CY2016Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	3830618
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49114219	shares
CY2016Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	175584	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49114219	shares
CY2016Q4	us-gaap	Common Stock Share Subscribed But Unissued Subscriptions Receivable CommonStockShareSubscribedButUnissuedSubscriptionsReceivable	30563
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	49114
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4309166
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1343443
CY2016Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	141086
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	87462
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-94669272
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	2965723
CY2016Q4	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	66377
CY2017Q2	ogen	Number Of Accredited Investors NumberOfAccreditedInvestors	3	Investor
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Concentrations</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> In June of 2016, the Company sold its consumer probiotics business, as such the Company is no longer dependent on key suppliers to continue to operate the consumer probiotics business.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. As of September 30, 2017, the uninsured portion of this balance was $4,081,569. As of December 31, 2016, the uninsured portion of this balance was $3,830,618.</p> </div>
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1157164
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2988
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3847886
	us-gaap	Operating Expenses OperatingExpenses	5305935
	dei	Entity Registrant Name EntityRegistrantName	ORAGENICS INC
	dei	Entity Central Index Key EntityCentralIndexKey	0001174940
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	53342
	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	0
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Type DocumentType	10-Q
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	188726
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2581586
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5270792
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.11
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	317179
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-5270792
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	456496
	us-gaap	Interest Expense InterestExpense	164560
	us-gaap	Investment Income Interest InvestmentIncomeInterest	6771
	us-gaap	Interest Paid InterestPaid	3040
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	118237
	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>1. Organization</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Oragenics, Inc. (formerly known as Oragen, Inc.) (the “Company” or “we”) was incorporated in November, 1996; however, operating activity did not commence until 1999. We are focused on becoming a leader in developing novel antibiotics against infectious disease and on developing effective treatments for oral mucositis.</p> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5005050
	us-gaap	Net Income Loss NetIncomeLoss	-5270792
	us-gaap	Notes Assumed1 NotesAssumed1	172047
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5305935
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	35143
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7194
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	2400000
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	2935792
	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	-110354
	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	-1408115
	us-gaap	Restricted Stock Expense RestrictedStockExpense	114576
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2724349
	us-gaap	Revenues Revenues	0
	ogen	Class Of Warrant Expired ClassOfWarrantExpired	175584	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	422206
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	71200	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.37
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1056000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	386666	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	307630
	dei	Trading Symbol TradingSymbol	OGEN
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49246673	shares
	us-gaap	Unrealized Gain Loss On Derivatives And Commodity Contracts UnrealizedGainLossOnDerivativesAndCommodityContracts	188726
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The principal areas of estimation reflected in the financial statements are anticipated milestone payments, stock based compensation, valuation of warrants, and income tax valuation allowance. Inventory obsolescence reserve, sales returns and allowances and the allowance for doubtful accounts were the principal areas of estimation that had been reflected in the financial statements related to discontinued operations.</p> </div>
	ogen	Proceeds From Payment Of Stock Subscription Receivable ProceedsFromPaymentOfStockSubscriptionReceivable	30563
	ogen	Class Of Warrant Granted In Period ClassOfWarrantGrantedInPeriod	11129031	shares
	ogen	Par Value Of Restricted Shares Issued ParValueOfRestrictedSharesIssued	160
	ogen	Class Of Warrant Exercised ClassOfWarrantExercised	0	shares
	ogen	Fair Market Value Of Warrants Issued For Financial Advisory Services FairMarketValueOfWarrantsIssuedForFinancialAdvisoryServices	118237
	ogen	Number Of Warrants Issued For Financial Advisory Services NumberOfWarrantsIssuedForFinancialAdvisoryServices	483870	shares
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-42761
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	76037
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3578
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	55402
	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	1453744
	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	0
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	20882
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2855822
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5813133
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	1474626
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.13
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-44850
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-5813133
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.03
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-198557
	us-gaap	Interest Expense InterestExpense	2947
	us-gaap	Investment Income Interest InvestmentIncomeInterest	22554
	us-gaap	Interest Paid InterestPaid	2769
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1675019
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3512042
	us-gaap	Operating Expenses OperatingExpenses	5834597
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5111024
	us-gaap	Net Income Loss NetIncomeLoss	-4338507
	us-gaap	Notes Assumed1 NotesAssumed1	161125
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5834597
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	21464
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5435
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	27179
	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	450000
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	1250000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2640146
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2198
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43078989	shares
	ogen	Proceeds From Payment Of Stock Subscription Receivable ProceedsFromPaymentOfStockSubscriptionReceivable	984666
	ogen	Par Value Of Restricted Shares Forfeited ParValueOfRestrictedSharesForfeited	20
	ogen	Notes Issued For Stock NotesIssuedForStock	2000000
	ogen	Technology Access Fee Paid In Convertible Note Payable To Shareholder TechnologyAccessFeePaidInConvertibleNotePayableToShareholder	3126
	ogen	Par Value Of Restricted Shares Issued ParValueOfRestrictedSharesIssued	230
CY2016	ogen	Class Of Warrant Exercised ClassOfWarrantExercised	0	shares
CY2016Q3	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1200
CY2016Q3	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	0
	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	-112770
	us-gaap	Restricted Stock Expense RestrictedStockExpense	84000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2978775
	us-gaap	Share Based Compensation ShareBasedCompensation	468992
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.72
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	700000	shares
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	384992
CY2016Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	42566
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1101870
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2005573
CY2016Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	42566
CY2016Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.04
CY2016Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2005573
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2016Q3	us-gaap	Interest Expense InterestExpense	1291
CY2016Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	18526
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	2026670
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-1963007
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2026670
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	21097
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5062
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	924800
CY2016Q3	us-gaap	Share Based Compensation ShareBasedCompensation	225427
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.00
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49114219	shares
CY2017Q3	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	588
CY2017Q3	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	0
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2017Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-42918
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	925043
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2067230
CY2017Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.04
CY2017Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2067230
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2017Q3	us-gaap	Interest Expense InterestExpense	105894
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	3004
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	1921520
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-2067230
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1921520
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-145710
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	686
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	996477
CY2017Q3	us-gaap	Share Based Compensation ShareBasedCompensation	127440
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.00
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	49274219	shares

Files In Submission

Name	View Source	Status
0001193125-17-327138-index-headers.html	Edgar Link	pending
0001193125-17-327138-index.html	Edgar Link	pending
0001193125-17-327138.txt	Edgar Link	pending
0001193125-17-327138-xbrl.zip	Edgar Link	pending
d460351d10q.htm	Edgar Link	pending
d460351dex311.htm	Edgar Link	pending
d460351dex312.htm	Edgar Link	pending
d460351dex321.htm	Edgar Link	pending
d460351dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ogen-20170930.xml	Edgar Link	completed
ogen-20170930.xsd	Edgar Link	pending
ogen-20170930_cal.xml	Edgar Link	unprocessable
ogen-20170930_def.xml	Edgar Link	unprocessable
ogen-20170930_lab.xml	Edgar Link	unprocessable
ogen-20170930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OGEN
ORAGENICS INC Stock $ogen

2017 Q4 Form 10-Q Financial Statement

#000119312517327138 Filed on October 31, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OGEN ORAGENICS INC Stock $ogen

2017 Q4 Form 10-Q Financial Statement

#000119312517327138 Filed on October 31, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OGEN
ORAGENICS INC Stock $ogen